Clinical trial NCT01740089: Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C
Official title: Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Hepatitis
Hepatitis C
Keywords: Hepatitis C
Cepeginterferon alfa
Peginterferon
Treatment
Lead sponsor: Biocad
Sponsor class: INDUSTRY
First posted: 2012-12-04
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to determine therapeutic dose of Algeron.

Detailed description: After 12 weeks of treatment, an assessment of treatment efficacy was performed, i.e. rates of rapid (after 4 weeks) and early (after 12 weeks) virologic responses according to serum HCV RNA level PCR data. In patients without virologic response after 12 weeks, AVT was discontinued, and they were withdrawn from the study. Patients with EVR were enrolled in a follow-up period. During the follow-up period, patients of the first and the second group will receive Algeron in the selected therapeutic dose in combination with ribavirin, patients of the third group - PegIntron in combination with ribavirin during 12 or 36 weeks (depending on a genotype of the virus), afterwards they will be followed up without therapy for 24 weeks.

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent to participate in the study.
2. Hepatitis С virus infection (genotypes 1а, 1b, 2, 3, 4) confirmed by a positive quantitative PCR (HCV RNA \> 50 IU/ml).
3. Males and females aged from 18 to 70 years inclusive.
4. Body mass index of 18 - 30 kg/m inclusive.
5. Increased ALT level (\> 40, \< 400 IU/L), documented at least twice within the last 6 months.
6. Preserved protein synthetic liver function (i.e. INR \< 1.7, albumin \> 35 g/l).
7. No signs of hepatic encephalopathy or abdominal fluid retention according to clinical and ultrasound examination.
8. Fertile patients and their partners agree to use barrier contraception throughout the study and 7 months after its completion.

Exclusion Criteria:

1. Intolerance of IFN alpha formulations, ribavirin or any components of these drugs according to the past medical history.
2. Infection by hepatitis B virus or HIV.
3. Past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations.
4. Administration of interferons and/or interferon inducing drugs for any indication within 1 month prior to the enrollment into the study.
5. Cholestatic hepatitis (conjugated bilirubin, alkaline phosphatase, ALT levels of more than 5 ULN).
6. Decompensated liver cirrhosis confirmed by laboratory findings (Child-Pugh class B, С) or ultrasound examination.
7. Any documented autoimmune diseases.
8. Hematologic (hemoglobin \< 130 g/L for males and \< 120 g/L for females; neutrophils \< 1.5 х109/L; platelets \< 90 х109/L) or biochemical abnormalities (creatinine level of more than 1.5 ULN, creatinine clearance less than 50 mL/min).
9. Documented diagnosis of hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).
10. Heavy depression, any other mental disorders, which in the Investigator's opinion can be contraindications for antiviral treatment.
11. Epilepsy and/or other functional disorders of the central nervous system.
12. Abnormal thyroid function (TTH level beyond the normal values).
13. Malignant neoplasms.
14. Pregnancy, lactation period.
15. Severe comorbidities (for example, severe hypertension, severe coronary heart disease, decompensated diabetes mellitus), which in the Investigator's opinion can be contraindications for antiviral treatment.
16. Documented rare hereditary diseases, such as intolerance of lactose, sucrose, fructose, lactase deficiency or glucose-galactose malabsorption.
17. Current alcohol or drug abuse, which in the Investigator's opinion can be contraindications for antiviral treatment or restrict treatment compliance.
18. Simultaneous participation in other clinical trials or prior participation in this or another clinical trial within less than 30 days after its completion.

Primary outcomes:
measure: Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.
timeFrame: 12 weeks
Secondary outcomes:
measure: Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) After 4 Weeks of Treatment.
timeFrame: 4 weeks
measure: Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.
timeFrame: 24 weeks after last dose of study treatment
measure: Number of Patients Who Have Undetectable HCV RNA (< 15 IU/ml) at the End of Treatment.
timeFrame: After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4.
Other outcomes:
measure: Immunogenicity
timeFrame: Weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment
Locations:
city: Moscow
country: Russian Federation
facility: Moscow State University of Medicine and Dentistry
Study officials:
affiliation: Moscow State University of Medicine and Dentistry
name: Olga Znoyko, professor
role: PRINCIPAL_INVESTIGATOR
affiliation: The First Moscow State Sechenov Medical University
name: Marina Maevskaya, professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Health Department "Center for Prevention and Control of AIDS and Infectious Diseases"
name: Svetlana Kizhlo
role: PRINCIPAL_INVESTIGATOR
affiliation: Smolensk State Medical Academy
name: Natalia Petrochenkova
role: PRINCIPAL_INVESTIGATOR
affiliation: Moscow State University of Medicine and Dentistry
name: Semen Maximov
role: PRINCIPAL_INVESTIGATOR
affiliation: Kazan State Medical University
name: Firaja Nagimova
role: PRINCIPAL_INVESTIGATOR
affiliation: 7. St. Petersburg State Institution of Health "Clinical Infectious Diseases Hospital named SP Botkin"
name: Vladimur Yakovlev
role: PRINCIPAL_INVESTIGATOR
References: